Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-16
2010-02-02
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S106000, C544S355000, C544S359000, C546S152000, C546S279700, C548S202000, C548S248000, C548S253000, C548S263200, C548S304700, C548S341500, C548S361100, C548S374100, C548S490000, C548S564000, C548S579000, C549S051000, C549S059000, C549S505000, C585S026000
Reexamination Certificate
active
07655680
ABSTRACT:
Thiazole compounds for inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4. The compounds of the invention are represented by general formula (1):wherein A is any one of the following groups (i) and (ii): (i) —CO—B— wherein B is a C1-6alkylene group and (ii) —CO—Ba— wherein Ba is a C2-6alkenylene group, and include optical isomers and salts of the compounds.
REFERENCES:
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4826990 (1989-05-01), Musser
patent: 5643932 (1997-07-01), Chihiro
patent: 5814651 (1998-09-01), Duplanter
patent: 1 396 487 (2004-03-01), None
patent: 1400515 (2004-03-01), None
patent: 1-143856 (1989-06-01), None
patent: 5-51318 (1993-03-01), None
patent: 8-501318 (1996-02-01), None
patent: WO 94/12461 (1994-06-01), None
patent: WO 98/08830 (1998-03-01), None
patent: WO 03/002540 (2003-01-01), None
patent: WO 2004/014903 (2004-02-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Mauro M. Teixeira et al., “Phosphodiesterase (PFE) 4 inhibitors: anti-inflammatory drugs of the future?” Trends Pharmacol. Sci 18: 164-170, 1997.
John E. Souness et al., “Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors,” Immunopharmacology 47: 127-162, 2000.
David M. Essayan, “Cyclic nucleotide phosphodiesterases,” J. Allergy. Clin. Immunol. 108: 671-680, 2001.
Donald H. Maurice et al., Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of cardiovascular system, Mol. Pharmacol. 64: 533-546, 2003.
Theodore J. Torphy, “Phosphodiesterase isozymes Molecular targets for novel antiasthma agents,” Am. J. Respir. Crit. Care. Med. 157: 351-270, 1998.
M.A. Giembycz, “Development status of secodn generation PDE 4 inhibitors for asthma and COPD: the story so far,” Monaldi. Arch. Chest Dis. 57: 48-64, 2002.
W. Krause et al, “Anti-inflammatory activity of rolipram in a rat ear edema model,” Arzneimittelforschung 44: 163-165, 1994.
Laura Revel et al., “CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma,” Eur. J. Pharmacol. 229: 45-53, 1992.
Stephen J. Newsholme et al., “cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva,” Inflammation 17: 25-31, 1993.
N. Sommer et al., “The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis,” Nat. Med. 1: 244-248, 1995.
N. Sommer et al., “Therapeutical potential of phosphodiesterase type 4-inhibition in chronic autoimmune demyelinating disease,” J. Neuroimmunol. 79: 54-61, 1997.
L. Sekut et al., “Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation,” Clin. Exp. Immunol. 100: 126-132, 1995.
U. Nyman et al., “Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram,” Clin. Exp. Immunol. 108: 415-419, 1997.
Susan E. Ross et al., “Suppression of TNF-α expression, inhibition of Th1 activity and amelioration of collagen-induced arthritis by rolipram,” J. Immunol. 159: 6253-6259, 1997.
Joseph A. Beavo, “Cyclic Nucleotide Phosphodiesterase: Functional Implications of Multiple Isoforms,” Physiol. Rev. 75: 725-748, 1995.
J-C Renauld, “New insights into the role of cytokines in asthma,” J. Clin. Pathol. 54: 577-589, 2001.
A.M. Reimold, “TNF-α as therapeutic target: New drugs, more applications,” Curr. Drug Targets Inflamm. Allergy 1: 377-392, 2002.
Andrew G. Jarnicki et al., “T helper type-2 cytokine responses: potential therapeutic targets,” Curr. Opin. Pharmacol. 3: 449-455, 2003.
Cora Vizcarra, “New Perspectives and Emerging Therapies for Immune-mediated Inflammatory Disorders,” J. Infus. Nurs. 26: 319-325, 2003.
Michael S. Malamas et al., “Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of 5-Lipoxygenase,” J. Med. Chem., 1996, vol. 39, No. 1, pp. 237-245.
Chihiro Masatoshi
Fujita Kazuhiko
Haruta Junpei
Hiyama Hidetaka
Ishiyama Hironobu
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Otsuka Pharmaceutical Co. Ltd.
Willis Douglas M
Wilson James O
LandOfFree
Thiazole compound and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazole compound and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazole compound and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232269